Research

Nautilus Biotech and Microbix Biosystems Sign Distribution Agreement for High-producer Cells

Published in Gene Therapy Weekly, February 14th, 2002

Nautilus Biotech (Evry, France) and Microbix Biosystems, Inc., (Toronto, Canada) have signed a distribution agreement for academic applications of NautCell, a high-producer cell line for recombinant Adeno-associated vectors.

NautCell has been developed by Nautilus using its proprietary high-throughput platform biomics technology for cell-directed evolution, after more than 40,000 individual rAAV viral infections with rAAV produced by cell clones obtained from the Microbix' 293 HEK cell line.

NautCell displays a stable 1-2 logs higher productivity for rAAV compared with the parental 293 HEK cells, and is designed to meet the rapidly growing rAAV...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Gene Therapy Weekly

Source: Gene Therapy Weekly (2002-02-14)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry